Hormone replacement therapy may protect against eye disease

November 13, 2017, American Academy of Ophthalmology

Women who took estrogen-only hormone replacement therapy after ovary removal had a lower risk of developing glaucoma, according to research presented today at AAO 2017, the 121st Annual Meeting of the American Academy of Ophthalmology.

This research, which was conducted at Wilmer Eye Institute at Johns Hopkins University, Stanford University, and the University of California, San Francisco, appears to reaffirm earlier research that showed a higher lifetime exposure to is linked to a lower risk of developing , suggesting a possible new preventative treatment path. It has been hypothesized that estrogen deprivation from ovary removal may be a risk factor for developing glaucoma, one of the leading causes of blindness, affecting nearly 60 million worldwide.

The researchers conducted their study using 2005-2008 data from the National Health and Nutrition Examination Survey NHANES. The survey included 3,406 female participants aged 40 years or older from across the United States who completed the survey's vision and reproductive health questionnaire and underwent eye exams.

They found that earlier age at ovary removal was associated with a 6 percent per year higher chance of self-reported glaucoma in African-American women. However, all women who had their ovaries removed and used estrogen-only hormone replacement therapy had a 9 percent lower odds of having glaucoma each year they took estrogen-only hormone replacement therapy.

"While this study doesn't directly answer the question of why estrogen appears to guard women from glaucoma, it seems likely that estrogen may protect against the nerve damage that happens to the eye in glaucoma patients," said lead researcher Mary Qiu, M.D., an ophthalmologist at Wilmer Eye Institute. "Future studies should address the potential role of glaucoma screening and in undergoing ovary removal."

Previous studies have shown that a range of factors that reduce a woman's exposure to estrogen over her lifetime - starting menstruation at an older age, using oral contraceptives, going through menopause at a younger age or having their ovaries removed at a younger age - are all associated with a higher risk of developing glaucoma.

Explore further: Long-term oral contraceptive users are twice as likely to have serious eye disease

Related Stories

Long-term oral contraceptive users are twice as likely to have serious eye disease

November 18, 2013
Research presented today, at the 117th Annual Meeting of the American Academy of Ophthalmology in New Orleans, has found that women who have taken oral contraceptives for three or more years are twice as likely to suffer ...

Hormone replacement therapy may be beneficial for women's memory

November 2, 2017
A type of hormone replacement therapy may protect memory for some women, according to a new USC-led study.

Major increase in U.S. glaucoma cases expected by 2030

January 9, 2017
(HealthDay)—Glaucoma affects more than three million Americans, but that number is expected to surge to more than four million by 2030, according to the Glaucoma Research Foundation.

Postmenopausal hormone Rx may cut risk for glaucoma

February 1, 2014
(HealthDay)—Use of estrogen-only postmenopausal hormone (PMH) treatment may help reduce the risk for primary open-angle glaucoma (POAG), according to research published online Jan. 30 in JAMA Ophthalmology.

Postmenopausal hormone therapy exceeding ten years may protect from dementia

February 16, 2017
Postmenopausal estrogen-based hormone therapy lasting longer than ten years was associated with a decreased risk of Alzheimer's disease in a large study carried out at the University of Eastern Finland.

The role of dosage in assessing risk of hormone therapy for menopause

July 27, 2017
When it comes to assessing the risk of estrogen therapy for menopause, how the therapy is delivered—taking a pill versus wearing a patch on one's skin—doesn't affect risk or benefit, researchers at UCLA and elsewhere ...

Recommended for you

Microglia protect sensory cells needed for vision after retinal detachment

June 18, 2018
A research team at Massachusetts Eye and Ear has shown that microglia, the primary immune cells of the brain and retina, play a protective role in response to retinal detachment. Retinal detachment and subsequent degeneration ...

161 genetic factors for myopia identified

June 15, 2018
The international Consortium for Refractive Error and Myopia (CREAM) recently published the largest-ever genetic study of myopia in Nature Genetics. Researchers from the Gutenberg Health Study at the Medical Center of Johannes ...

Normal eye dominance is not necessary for restoring visual acuity in amblyopia

June 7, 2018
Amblyopia, commonly known as "lazy eye," is a visual disorder common in children. The symptoms often are low acuity in the affected or "lazy" eye and impaired depth perception. Researchers have long believed that the impaired ...

Education linked to higher risk of short-sightedness

June 6, 2018
Spending more years in full time education is associated with a greater risk of developing short-sightedness (myopia), finds a study published by The BMJ today.

First 3D-printed human corneas

May 29, 2018
The first human corneas have been 3-D printed by scientists at Newcastle University, UK.

Satellite imaging techniques may help reduce preventable vision loss

May 11, 2018
By adapting pattern recognition techniques used to assess satellite images, scientists have devised a novel way to diagnose blinding eye diseases, such as age-related macular degeneration.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.